Incruse Ellipta Inhaler Approved for COPD GlaxoSmithKline announced that the FDA has approved Incruse Ellipta (umeclidinium) inhaler for the long-term, once-daily, maintenance treatment of airflow ...

LONDON, April 30, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Incruse™ Ellipta ® (umeclidinium) as an ...

Umeclidinium 62.5mcg; per inhalation; dry pwd for oral inhalation; contains lactose. Incruse Ellipta should be stored at room temperature between 68°-77° F (20°-25° C); excursions permitted from ...

Arnuity™ Ellipta® now available in the US for once-daily treatment of asthma. Incruse® Ellipta® now available in the US for once-daily treatment for COPD. Arnuity ™ Ellipta (fluticasone furoate ...

GSK and Theravance announce positive data from two studies evaluating the efficacy and safety of Incruse™ Ellipta® when added to Relvar®/Breo® Ellipta® in patients with COPD GlaxoSmithKline plc ...

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 11, 2014) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from ...

LONDON — GlaxoSmithKline on Wednesday announced that the Food and Drug Administration approved Incruse Ellipta (umeclidinium), which is used for the treatment of airflow obstruction in patients with ...

The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis. The FDA late Monday approved sales of ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Do not use if you have ever had an allergic reaction to INCRUSE ...

The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis. The FDA late Monday approved sales of ...